1stOncology™: Cancer Intelligence Service – Page 14474 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Intrexon has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Intrexon, 2018, MAR 1, 2018, View Source [SID1234524278]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Juno has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Juno, 2018, MAR 1, 2018, View Source [SID1234524277]).

10-K – Annual report [Section 13 and 15(d), not S-K Item 405]

Sangamo Therapeutics has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission (Filing, 10-K, Sangamo Therapeutics, 2018, MAR 1, 2018, View Source [SID1234524276]).

Tanvex Name Change

On March 1, 2018 Tanvex BioPharma, Inc., reported that it will be changing the name of La Jolla Biologics, Inc., its wholly owned subsidiary located in San Diego, CA, to align the subsidiary’s identity with the parent company (Press release, Tanvex BioPharma, MAR 1, 2018, View Source [SID1234524594]). Effective March 01, 2018, La Jolla Biologics, Inc. will start using the name Tanvex BioPharma USA, Inc. The name change has no impact on the functional responsibilities or day to day operations of the subsidiary.

Histogenics Corporation to Report 2017 Financial Results on March 15, 2018

On March 1,2018 Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, reported that financial results for the quarter and year ended December 31, 2017, on March 15, 2018, before the market opens (Press release, Histogenics, MAR 1, 2018, View Source;p=RssLanding&cat=news&id=2335634 [SID1234524304]).

Histogenics’ management will host a conference call on Thursday, March 15, 2018 at 8:30 a.m. EDT. A question-and-answer session will follow Histogenics’ remarks. To participate on the live call, please dial (877) 930-8064 (domestic) or (253) 336-8040 (international) and provide the conference ID "7394538" five to ten minutes before the start of the call.

To access a live audio webcast of the presentation on the "Investor Relations" page of the Histogenics website, please click here. A replay of the webcast will be archived on Histogenics’ website for approximately 45 days following the presentation.